WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Trump Says Anthropic No Longer Seen as National Security Threat 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
NEW YORK, Feb. 01, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) securities between March 5, 2015 and September 8, 2015.
Click here to learn about the case: http://docs.wongesq.com/TTPH-Info-Request-Form-1089. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/TTPH-Info-Request-Form-1089.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
